Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
QHRD106 Injection
DRUG
2 trials
Sponsors
Changzhou Qianhong Bio-pharma Co., Ltd.
Conditions
Acute Ischemic Stroke
Phase 1
Study to Assess PK, Safety and Tolerability in Healthy Subjects
Completed
NCT06380699
Changzhou Qianhong Bio-pharma Co., Ltd.
Acute Ischemic Stroke
Start: 2023-03-16
End: 2023-12-25
Updated: 2024-07-24
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
Completed
NCT06388772
Changzhou Qianhong Bio-pharma Co., Ltd.
Acute Ischemic Stroke
Start: 2021-07-05
End: 2023-01-06
Updated: 2024-07-24
Related Papers
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke
Expert Opinion on Investigational Drugs
2024-11-15